bupropion has been researched along with efavirenz in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Desta, Z; Guo, Y; Ogburn, ET; Xu, C | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Greenblatt, DJ; Hesse, LM; Shader, RI; von Moltke, LL | 1 |
| Antoniou, T; Park-Wyllie, LY | 1 |
| Ingelman-Sundberg, M; Josephson, F; Lundgren, S; Rane, A; Sönnerborg, A; Ståhle, L; Wang, J | 1 |
| Astuccio, AV; Obach, RS; Walsky, RL | 1 |
| Alfaro, RM; Formentini, E; Maldarelli, F; Natarajan, V; Penzak, SR; Robertson, SM | 1 |
| Ashton, M; Asimus, S | 1 |
| Niu, RJ; Zhang, HX; Zhang, JL; Zheng, QC | 1 |
| Amunugama, H; Ballou, DP; Hollenberg, PF; Kenaan, C; Sridar, C; Zhang, H | 1 |
| Hanioka, N; Koeda, A; Masuda, K; Mayumi, K; Miyata, A; Naito, S; Narimatsu, S | 1 |
1 review(s) available for bupropion and efavirenz
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for bupropion and efavirenz
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Topics: Alkynes; Alleles; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biotransformation; Bupropion; Catalysis; Clopidogrel; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochromes b5; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyrimidines; Substrate Specificity; Ticlopidine; Triazoles; Voriconazole | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Topics: Alkynes; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Bupropion; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Protease Inhibitors; Humans; Hydroxylation; Inhibitory Concentration 50; Microsomes, Liver; Nelfinavir; Oxazines; Oxidoreductases, N-Demethylating; Reverse Transcriptase Inhibitors; Ritonavir | 2001 |
Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Benzoxazines; Bupropion; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Oxazines; Retrospective Studies; Ritonavir; Seizures | 2003 |
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.
Topics: Africa; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Black People; Bupropion; Cyclopropanes; Cytochrome P-450 CYP2B6; DNA Mutational Analysis; Humans; Oxazines; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Sweden; Turkey | 2006 |
Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.
Topics: Algorithms; Alkynes; Antidepressive Agents, Second-Generation; Antifungal Agents; Area Under Curve; Benzoxazines; Bupropion; Clopidogrel; Clotrimazole; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Itraconazole; Kinetics; Microsomes, Liver; Molecular Structure; Oxazines; Platelet Aggregation Inhibitors; Raloxifene Hydrochloride; Reverse Transcriptase Inhibitors; Selective Estrogen Receptor Modulators; Selective Serotonin Reuptake Inhibitors; Sertraline; Ticlopidine; Xenobiotics | 2006 |
Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Topics: Adult; Alkynes; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Bupropion; Cyclopropanes; Cytochrome P-450 CYP2B6; Delayed-Action Preparations; Drug Interactions; Enzyme Induction; Female; Genetic Variation; Humans; Hydroxylation; Male; Middle Aged; Oxidoreductases, N-Demethylating; Pharmacogenetics; Young Adult | 2008 |
Artemisinin--a possible CYP2B6 probe substrate?
Topics: Alkynes; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Antimalarials; Artemisinins; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Bupropion; Chromatography, High Pressure Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Humans; Hypnotics and Sedatives; In Vitro Techniques; Microsomes, Liver; Oxidoreductases, N-Demethylating; Propofol; Spectrophotometry, Ultraviolet | 2009 |
Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods.
Topics: Alkynes; Benzoxazines; Binding Sites; Bupropion; Butanes; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Humans; Hydrogen Bonding; Molecular Conformation; Molecular Dynamics Simulation; Pharmaceutical Preparations; Phenols; Propofol; Protein Binding; Substrate Specificity | 2011 |
Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex
Topics: Alkynes; Animals; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Bupropion; Catalysis; Chlorocebus aethiops; COS Cells; Coumarins; Cyclopropanes; Cytochrome P-450 CYP2B6; Electron Transport; Escherichia coli; Ferric Compounds; Genetic Variation; Kinetics; Mutagenesis; Mutation; NADPH-Ferrihemoprotein Reductase; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; tert-Butylhydroperoxide | 2011 |
Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions.
Topics: Alkynes; Amino Acid Sequence; Animals; Aryl Hydrocarbon Hydroxylases; Base Sequence; Benzoxazines; Bupropion; Callithrix; Cloning, Molecular; Cyclopropanes; Cytochrome P-450 CYP2B6; Humans; Hydroxylation; Insecta; Macaca fascicularis; Microsomes, Liver; Molecular Sequence Data; Oxidoreductases, N-Demethylating; Structure-Activity Relationship | 2013 |